Rosen N - Search Results

1

A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.

Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. Huron DR, et al. Among authors: rosen n. Clin Cancer Res. 2003 Apr;9(4):1267-73. Clin Cancer Res. 2003. PMID: 12684394

2

A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N. Sepp-Lorenzino L, et al. Among authors: rosen n. Cancer Res. 1995 Nov 15;55(22):5302-9. Cancer Res. 1995. PMID: 7585592

3

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.

Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N. Moasser MM, et al. Among authors: rosen n. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1369-74. doi: 10.1073/pnas.95.4.1369. Proc Natl Acad Sci U S A. 1998. PMID: 9465021 Free PMC article.

4

A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.

Sepp-Lorenzino L, Rosen N. Sepp-Lorenzino L, et al. Among authors: rosen n. J Biol Chem. 1998 Aug 7;273(32):20243-51. doi: 10.1074/jbc.273.32.20243. J Biol Chem. 1998. PMID: 9685373 Free article.

5

Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.

Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. Moasser MM, et al. Among authors: rosen n. Cancer Res. 1999 Dec 15;59(24):6145-52. Cancer Res. 1999. PMID: 10626805

6

Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.

Zheng FF, Kuduk SD, Chiosis G, Münster PN, Sepp-Lorenzino L, Danishefsky SJ, Rosen N. Zheng FF, et al. Among authors: rosen n. Cancer Res. 2000 Apr 15;60(8):2090-4. Cancer Res. 2000. PMID: 10786665

7

Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.

Srethapakdi M, Liu F, Tavorath R, Rosen N. Srethapakdi M, et al. Among authors: rosen n. Cancer Res. 2000 Jul 15;60(14):3940-6. Cancer Res. 2000. PMID: 10919672

8

Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.

Münster PN, Srethapakdi M, Moasser MM, Rosen N. Münster PN, et al. Among authors: rosen n. Cancer Res. 2001 Apr 1;61(7):2945-52. Cancer Res. 2001. PMID: 11306472

9

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.

Münster PN, Basso A, Solit D, Norton L, Rosen N. Münster PN, et al. Among authors: rosen n. Clin Cancer Res. 2001 Aug;7(8):2228-36. Clin Cancer Res. 2001. PMID: 11489796

10

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

Moasser MM, Basso A, Averbuch SD, Rosen N. Moasser MM, et al. Among authors: rosen n. Cancer Res. 2001 Oct 1;61(19):7184-8. Cancer Res. 2001. PMID: 11585753

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

741 results

Search Page

Filters